- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06497504
Studie av Bepirovirsen hos deltagare som lever med humant immunbristvirus och kronisk hepatit B-virusinfektion (B-Focus) (B-Focus)
En multicenter, randomiserad, dubbelblind, placebokontrollerad studie för att bedöma effektiviteten och säkerheten av behandling med bepirovirsen hos deltagare som lever med humant immunbristvirus och kronisk hepatit B-virusinfektion på antiretroviral behandling
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Almagro, Argentina, C1427CEA
- GSK Investigational Site
-
Buenos Aires, Argentina, 1023
- GSK Investigational Site
-
Buenos Aires, Argentina, C1425AGC
- GSK Investigational Site
-
Buenos Aires, Argentina, C1181ACI
- GSK Investigational Site
-
La Plata, Argentina, B1900AVG
- GSK Investigational Site
-
Rosario, Argentina, S2002KDR
- GSK Investigational Site
-
-
-
-
-
Aracaju, Brasilien, 49060-010
- GSK Investigational Site
-
Campinas, Brasilien, 13034-685
- GSK Investigational Site
-
Curitiba, Brasilien, 80810-050
- GSK Investigational Site
-
Manaus, Brasilien, 69040-000
- GSK Investigational Site
-
Salvador, Brasilien, 40110-060
- GSK Investigational Site
-
São Paulo, Brasilien, 04121-000
- GSK Investigational Site
-
-
-
-
-
Marseille, Frankrike, 13003
- GSK Investigational Site
-
Melun, Frankrike, 77000
- GSK Investigational Site
-
Montpellier, Frankrike, 34295
- GSK Investigational Site
-
Nantes, Frankrike, 44093
- GSK Investigational Site
-
Paris, Frankrike, 75018
- GSK Investigational Site
-
Paris, Frankrike, 75012
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, Förenta staterna, 93301
- GSK Investigational Site
-
San Francisco, California, Förenta staterna, 94115
- GSK Investigational Site
-
-
Florida
-
Orlando, Florida, Förenta staterna, 32803-1851
- GSK Investigational Site
-
West Palm Beach, Florida, Förenta staterna, 33409
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55415
- GSK Investigational Site
-
-
New Jersey
-
Hillsborough, New Jersey, Förenta staterna, 08844
- GSK Investigational Site
-
-
-
-
-
Genova, Italien, 16132
- GSK Investigational Site
-
Milan, Italien, 20157
- GSK Investigational Site
-
Milan, Italien, 20162
- GSK Investigational Site
-
Naples, Italien, 80131
- GSK Investigational Site
-
Roma, Italien, 00153
- GSK Investigational Site
-
Sassari, Italien, 07100
- GSK Investigational Site
-
-
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M5G 1K2
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2L 4P9
- GSK Investigational Site
-
Montreal, Quebec, Kanada, H4A 3J1
- GSK Investigational Site
-
Québec, Quebec, Kanada, G1V 4G2
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08036
- GSK Investigational Site
-
Córdoba, Spanien, 14004
- GSK Investigational Site
-
Madrid, Spanien, 28041
- GSK Investigational Site
-
Madrid, Spanien, 28040
- GSK Investigational Site
-
Madrid, Spanien, 28046
- GSK Investigational Site
-
Madrid, Spanien, 28031
- GSK Investigational Site
-
-
-
-
-
Bristol Avon, Storbritannien, BS10 5NB
- GSK Investigational Site
-
London, Storbritannien, E1 1BB
- GSK Investigational Site
-
London, Storbritannien, SE5 9RS
- GSK Investigational Site
-
London, Storbritannien, NW3 2QG
- GSK Investigational Site
-
-
-
-
-
Ekurhuleni, Sydafrika, 1459
- GSK Investigational Site
-
Johannesburg, Sydafrika, 2092
- GSK Investigational Site
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Sydafrika, 4052
- GSK Investigational Site
-
-
-
-
-
Banchiau Taipei, Taiwan, 220
- GSK Investigational Site
-
Kaohsiung City, Taiwan, 813
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Documented chronic hepatitis B virus (HBV) infection and documented human immunodeficiency virus (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
-
Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.
o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).
-
Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
-
Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA <90 international units per milliliter (IU/mL).
-
Plasma or serum HBsAg concentration >100 IU/mL and <=3000 IU/mL.
-
Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA <50 copies/mL.
-
Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm^3).
-
Alanine aminotransferase (ALT) <=2 times upper limit of normal (ULN).
Exclusion Criteria:
-
History of or suspected liver cirrhosis and/or evidence of cirrhosis.
-
Diagnosed or suspected hepatocellular carcinoma (HCC).
-
History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
-
Coinfection with:
-
Hepatitis C virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.
I. HCV treatment should have completed >12 months prior to Screening.
-
Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
-
-
Clinically significant abnormalities, aside from HIV-1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
-
Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
-
History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
-
History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an autoimmune condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
-
Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
-
Alcohol or drug abuse/dependence
-
Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone), other than a short course of therapy (<=2 weeks) or topical/inhaled steroid use.
-
Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is contraindicated should not be considered for enrolment in the study.
-
Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
-
Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti platelet agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
-
Prior treatment with bepirovirsen.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Participants receiving Bepirovirsen
Participants will receive bepirovirsen. |
Bepirovirsen will be administered. |
|
Placebo-jämförare: Participants receiving Placebo
Participants will receive placebo. |
Placebo will be administered. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
Tidsram: At study week 60
|
HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (<) lower limit of quantification (LLOQ). |
At study week 60
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication
Tidsram: At study week 24
|
HBV virologic response defined as HBsAg not detected and HBV DNA <LLOQ. |
At study week 24
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: GSK Clinical Trials, GlaxoSmithKline
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Blodburna infektioner
- Urogenitala sjukdomar
- Genitala sjukdomar
- Immunsystemets sjukdomar
- Infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Matsmältningssystemets sjukdomar
- Leversjukdomar
- Hepatit, Viral, Human
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- DNA-virusinfektioner
- Långsamma virussjukdomar
- Hepadnaviridae-infektioner
- Hepatit
- HIV-infektioner
- Förvärvat immunbristsyndrom
- Hepatit B
Andra studie-ID-nummer
- 219231
- 2023-509588-25 (Annan identifierare: EU CT Number)
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2023-509588-25-00 (Registeridentifierare: CTIS (EU))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Tidsram för IPD-delning
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kriterier för IPD Sharing Access
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .